Marti Technologies Inc. declined 1.09% in intraday trading. The FDA's appointment of George Tidmarsh as the top drug regulator, while not directly related to Marti Technologies, may have influenced investor sentiment in the broader biotech sector, potentially contributing to the stock's decline.
Comments
No comments yet